Organizations Filed Purposes:
THE GLOBAL HIV VACCINE ENTERPRISE (THE ENTERPRISE) IS AN ALLIANCE OF INDEPENDENT ORGANIZATIONS DEDICATED TO ACCELERATING THE DEVELOPMENT OF SAFE AND EFFECTIVE HIV VACCINES FOR USE GLOBALLY. IT MOVES VACCINE RESEARCH AND DEVELOPMENT FORWARD AMONG ORGANIZATIONS THROUGH COORDINATION, COLLABORATION, KNOWLEDGE-SHARING AND EFFORTS TO ATTRACT INTEREST, RESOURCES AND FUNDERS TO THE FIELD. SINCE 2014, THE ENTERPRISE HAS HOSTED THE SUCCESSFUL, NEW, BIENNIAL HIV RESEARCH FOR PREVENTION (HIVR4P) CONFERENCE. HIVR4P, THE WORLDS ONLY SCIENTIFIC MEETING DEDICATED EXCLUSIVELY TO BIOMEDICAL HIV PREVENTION RESEARCH, BRINGS TOGETHER POLICY EXPERTS, FUNDERS, STAKEHOLDERS AND OTHERS TO SHARE AND DISCUSS THE LATEST SCIENTIFIC DEVELOPMENTS FROM ALL HIV PREVENTION DISCIPLINES AND APPROACHES, INCLUDING THEIR DISTINCTIVE FEATURES, COMMONALITIES AND COMBINATION.
A UNIQUE ALLIANCE OF ORGANIZATIONS WORKING COLLABORATIVELY TO END THE AIDS EPIDEMIC BY ACCELERATING THE DEVELOPMENT OF SAFE AND EFFECTIVE PREVENTIVE HIV VACCINES.
MEETINGS/PROGRAM - A) STRATEGIC CONVENING/TIMELY TOPICS IN HIV VACCINES SERIES: THE SEARCH FOR A SAFE AND EFFECTIVE HIV VACCINE HAS PROGRESSED FURTHER AND FASTER IN THE LAST FEW YEARS THAN AT ANY TIME SINCE THE EPIDEMIC BEGAN. THIS PROGRESS POSES NEW QUESTIONS, NEW OPPORTUNITIES AND NEW CHALLENGES AS TO WHAT AND HOW THE HIV VACCINE RESEARCH ENDEAVOR SHOULD MOVE FORWARD. TO HELP IDENTIFY AND RESPOND TO UNRESOLVED AND EMERGING PRIORITY ISSUES AND MOVE HIV VACCINE R&D FORWARD, THE ENTERPRISE PRODUCES ITS TIMELY TOPICS IN HIV VACCINES SERIES. THROUGH AN OPEN CALL FOR PROPOSALS, THE ENTERPRISE IDENTIFIES THE MOST STRATEGIC NEEDS OF THE FIELD AND SPONSORS THINK TANKS, MEETINGS, FORUMS AND OTHER EVENTS IN ADDITION TO DEVELOPING USEFUL TOOLS TO TACKLE THESE ISSUES. ISSUES ADDRESSED TO DATE INCLUDE VACCINE-INDUCED SERO-POSITIVITY/ SERO-REACTIVITY, A MUCOSAL GUIDE, AND ANTIBODY DURABILITY, AMONG OTHERS. B) TO STRENGTHEN RECOGNITION OF THE ENTERPRISE MISSION, PROGRAMS, STAKEHOLDER GOALS AND ACHIEVEMENTS, AS WELL AS KEEP CURRENT ON THE STATE OF HIV VACCINE RESEARCH, THE ENTERPRISE SECRETARIAT PARTICIPATED IN VARIOUS SCIENTIFIC AND ADVISORY MEETINGS AND DISCUSSIONS WITH PARTNERS AND STAKEHOLDERS. THROUGH THESE INTERACTIONS, THE ENTERPRISE HELPED TO CONNECT PARTNERS, COORDINATE EFFORTS, SHARE INFORMATION, AND SUPPORT STAKEHOLDERS IN COORDINATED VACCINE RESEARCH AND DEVELOPMENT EFFORTS.
CONFERENCE - HIV RESEARCH FOR PREVENTION (R4P) CONFERENCE: THE GLOBAL HIV VACCINE ENTERPRISE (ENTERPRISE) BEGAN PREPARATIONS FOR THE HIVR4P CONFERENCE TO BE HELD FROM OCTOBER 21ST TO 25TH, 2018 IN MADRID, SPAIN. THIS BIENNIAL CONFERENCE IS THE LEADING GLOBAL FORUM FOR SCIENTIFIC EXCHANGE ON HIV VACCINE RESEARCH AND HELPS TO INCREASE COORDINATION IN OUR COLLECTIVE EFFORT TO DEVELOP AN HIV VACCINE. THE CONFERENCE WILL BE ATTENDED BY MORE THAN 1400 RESEARCHERS, FUNDERS, ADVOCATES, AND POLICYMAKERS, FEATURE DAILY PLENARY PRESENTATIONS BY LEADING RESEARCHERS AND CLINICIANS ALONG WITH SYMPOSIA AND ORAL ABSTRACT AND POSTER SESSIONS ADDRESSING EVERY ASPECT OF VACCINE DEVELOPMENT AND TESTING. HIVR4P 2018 WILL HOST MANY OPPORTUNITIES FOR YOUNG AND EARLY CAREER INVESTIGATORS TO SHARE IDEAS AND APPROACHES AND NETWORK WITH PEERS AND SENIOR RESEARCHERS.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Gabriella Scarlatti | Science Director (thru 12/17) | 40 | $330,298 |
| Yegor Voronin | Sr. Science Officer | 40 | $168,021 |
| Bargavi Thyagarajan | Science Officer | 40 | $116,734 |
| Howard Njoo | Board member | 1 | $0 |
| Lynn Morris | Board member | 1 | $0 |
| Yves Levy | Board member | 1 | $0 |
| Mark Feinberg | Board member | 1 | $0 |
| David Cook | Secretary and Treasurer | 1 | $0 |
| Gerald Voss | Vice President | 1 | $0 |
| Mitchell Warren | President | 1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/201843049349301809_public.xml